Our Science

Overcoming delivery challenges that limit promising new treatment modalities

Through an exclusive license with Harvard University, Vesigen’s therapeutic programs employ engineered ARMMs to deliver RNA, proteins, and gene-editing complexes to cells that are not otherwise accessible. Unlike existing delivery systems, which are limited by toxicity, immunogenicity, poor cell/tissue specificity, and reduced cellular activity due to endosomal trapping or endolysosomal processing, ARMMs technology overcomes these limitation to achieve safe and efficient functional delivery of therapeutic molecules.

Key Advantages of the ARMMs Delivery Platform

Our technology is based on a distinct class of extracellular vesicles that mediates inter-cellular and inter-tissue signaling within the human body. ARMMs (ARRestin-domain 1 Mediated Microvesicles) technology derives its name from the protein ARRestin Domain Containing Protein 1 (ARRDC1), and utilizes the latter protein as a unique handle to actively recruit payloads into the intraluminal space.

Precision Medicines Enabled

Engineered ARMMs represent a versatile platform for efficient delivery of gene editors, RNA and protein-based therapeutics.

This technology offers significant advantages over conventional delivery technologies, including lipid nanoparticles (LNPs) and viral vectors:

High loading capacity of multiple therapeutic payloads
High potency
Efficient biodistribution to otherwise inaccessible cell and tissue types, with potential to further tune tropism
Non-immunogenic and re-dosable
Low complexity and scalable manufacturing process

Functional delivery of gene editing complexes and therapeutic RNA molecules to multiple cell types has been demonstrated in vitro and in vivo

Engineered cells producing ARMMs loaded with green fluorescent protein (GFP)

Uptake of GFP-loaded ARMMs by recipient cells

Join our team

Explore current opportunities